James McMillen, MD
Infectious Disease · Atlanta, GANPI 1659470946
Payments from drug & device makers
Across 516 payments — averaging $342.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$152K
- Ferring Pharmaceuticals Inc.$9K
- Shionogi Inc$5K
- Tetraphase Pharmaceuticals, Inc.$4K
- La Jolla Pharmaceutical Company$2K
- Gilead$653
- plus $3K from 17 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 300 | $151,947 |
| Ferring Pharmaceuticals Inc. | 20 | $9,284 |
| Shionogi Inc | 8 | $4,912 |
| Tetraphase Pharmaceuticals, Inc. | 15 | $4,476 |
| La Jolla Pharmaceutical Company | 13 | $2,320 |
| Gilead | 22 | $653 |
| Merck | 27 | $625 |
| Viiv Healthcare Company | 24 | $527 |
| Astellas Pharma US Inc | 15 | $369 |
| Paratek Pharmaceuticals, Inc. | 13 | $292 |
| Melinta Therapeutics, LLC | 10 | $222 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $188 |
| Insmed, Inc. | 6 | $162 |
| Theratechnologies Inc. | 8 | $157 |
| Johnson & Johnson | 12 | $147 |
| Napo Pharmaceuticals Inc | 4 | $122 |
| CSL Behring | 3 | $82 |
| Pfizer | 4 | $73 |
| Janssen Products, LP | 1 | $60 |
| Shire North American Group Inc | 1 | $28 |
| Cumberland Pharmaceuticals, Inc. | 1 | $28 |
| Mylan Pharmaceuticals Inc. | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $12 |
How this compares
$176,705 in reported general payments places this provider in the 85th percentile of 260 infectious disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other infectious disease in Atlanta
- Mark MulliganAtlanta$4.6M
- Nadine RouphaelAtlanta$2.4M
- Leila HojatAtlanta$2.2M
- Kimberly WorkowskiAtlanta$2M
- Zandraetta Tims-CookAtlanta$878K
- Scott FridkinAtlanta$774K
- Colleen KelleyAtlanta$738K
- Leandro MenaAtlanta$733K
- Srilatha EdupugantiAtlanta$726K
- Larry AndersonAtlanta$694K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.